What is the appropriate apixaban (Elliquis) dosing regimen for portal vein thrombosis, including loading dose, maintenance dose, and adjustments for age ≥80 years, weight ≤60 kg, impaired renal function, and contraindications such as Child‑Pugh class C liver disease?

Apixaban Dosing for Portal Vein Thrombosis

For portal vein thrombosis in patients with compensated cirrhosis (Child-Pugh A or B), apixaban 10 mg orally twice daily for 7 days followed by 5 mg twice daily is a reasonable anticoagulant option, but it is contraindicated in Child-Pugh C cirrhosis and should be avoided in patients with gastric or gastroesophageal lesions. 1, 2

Standard Dosing Regimen

• Initial phase (Days 1-7): Apixaban 10 mg orally twice daily for exactly 7 days, without any preceding parenteral anticoagulation (no heparin bridge required). 3

• Maintenance phase (Day 8 onward): Apixaban 5 mg orally twice daily, continued until portal vein recanalization or liver transplantation. 3, 1

• No dose adjustment is required for the atrial fibrillation dose-reduction criteria (age ≥80 years, weight ≤60 kg, serum creatinine ≥1.5 mg/dL) when treating portal vein thrombosis, as these criteria apply only to stroke prevention in atrial fibrillation, not to venous thromboembolism. 4, 3

Child-Pugh Classification Restrictions

• Child-Pugh A or B cirrhosis: Direct oral anticoagulants including apixaban may be considered based on patient preference and convenience, as dosing is independent of INR monitoring. 1, 2

• Child-Pugh C cirrhosis: Apixaban is contraindicated due to hepatic disease associated with coagulopathy and clinically relevant bleeding risk. Low-molecular-weight heparin (LMWH) alone or as a bridge to vitamin K antagonist should be used instead. 2, 5

• Apixaban pharmacokinetics show a 2.27-fold increase in drug exposure in Child-Pugh B patients for rivaroxaban, but only a 1.09-fold increase for apixaban, suggesting a more favorable profile in moderate hepatic impairment. 5, 6

Renal Function Considerations

• Creatinine clearance ≥30 mL/min: No dose adjustment required for the standard VTE treatment regimen (10 mg BID × 7 days → 5 mg BID). 3, 7

• Creatinine clearance 15-29 mL/min: Apixaban may be used with caution at standard VTE doses, though data are limited and patients with CrCl <25 mL/min were excluded from pivotal trials. 4, 7

• Creatinine clearance <15 mL/min or dialysis: Apixaban should be avoided due to uncertain safety and efficacy, with risk of drug accumulation and spontaneous hemorrhage including pleural, pericardial, and intracranial bleeding. 4, 8

Treatment Duration and Monitoring

• Imaging surveillance: Obtain cross-sectional imaging (CT or MRI) every 3 months to assess thrombus response. 1

• Continue anticoagulation until complete clot resolution in non-transplant candidates, or until liver transplantation in transplant candidates. 1

• Observation without anticoagulation may be considered for intrahepatic portal vein branch thrombosis or <50% occlusion of main portal vein, with repeat imaging every 3 months. 1

• Anticoagulation is recommended for recent (<6 months) portal vein thrombosis with >50% occlusion or involvement of main portal vein or mesenteric vessels, particularly in transplant candidates or those with thrombus progression. 1

• Chronic portal vein thrombosis (>6 months) with complete occlusion and cavernous transformation does not benefit from anticoagulation. 1

Contraindications and Special Precautions

• Gastric or gastroesophageal tumors: Apixaban should be avoided due to increased hemorrhage risk; LMWH is preferred in this setting. 9

• Active bleeding: Apixaban is contraindicated in patients with active clinically significant bleeding. 3

• Thrombocytopenia: Anticoagulation should not be withheld for moderate thrombocytopenia (platelet count >50 × 10⁹/L) secondary to advanced liver disease. For platelet counts <50 × 10⁹/L, decisions should be individualized based on thrombus extent, progression risk, and bleeding risk factors. 2

• Drug interactions: Reduce apixaban dose by 50% when co-administered with combined P-glycoprotein and strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir). 4

Comparative Evidence for Portal Vein Thrombosis

• Direct oral anticoagulants, LMWH, and warfarin have all been used successfully for splanchnic portal vein thrombosis, with DOACs showing comparable efficacy and safety to traditional agents. 9

• In non-cirrhotic portal vein thrombosis, apixaban achieved 65% complete radiographic resolution rates, similar to rivaroxaban (65%) and enoxaparin (57%), and superior to warfarin (31%). 10

• DOACs were associated with significantly less major bleeding compared to warfarin (HR 0.20,95% CI 0.05-0.86, P=0.03) in portal vein thrombosis patients. 10

Common Pitfalls to Avoid

• Do not apply atrial fibrillation dose-reduction criteria (2.5 mg BID for age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL) to portal vein thrombosis treatment, as this results in under-dosing and increased thrombotic risk. 4

• Do not use apixaban in Child-Pugh C cirrhosis or in patients with hepatic disease associated with coagulopathy, as this significantly increases bleeding risk. 2, 5

• Do not omit the 7-day loading phase at 10 mg twice daily; starting directly at 5 mg twice daily is insufficient for acute thrombosis treatment. 3

• Do not delay anticoagulation for endoscopic variceal screening, as delays decrease the likelihood of portal vein recanalization. 1